LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.1 0.92

Buy Sell

Overview

Share price change

24h

Current

Min

1.07

Max

1.12

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+358.72% upside

Market Stats
By TradingEconomics
Market Cap	-2.3M 123M
Previous open	0.18
Previous close	1.1

News Sentiment

By Acuity

13%

87%

23 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 gru 2025, 22:02 UTC

Earnings

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 gru 2025, 21:46 UTC

Earnings

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 gru 2025, 23:52 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 gru 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 gru 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 gru 2025, 23:20 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 gru 2025, 23:15 UTC

Earnings

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 gru 2025, 22:59 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 gru 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 gru 2025, 22:40 UTC

Earnings

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 gru 2025, 22:06 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 gru 2025, 22:06 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 gru 2025, 22:02 UTC

Earnings

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 gru 2025, 22:00 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 gru 2025, 21:53 UTC

Earnings

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 gru 2025, 21:50 UTC

Acquisitions, Mergers, Takeovers

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 gru 2025, 21:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

10 gru 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 gru 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10 gru 2025, 21:45 UTC

Acquisitions, Mergers, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 gru 2025, 21:33 UTC

Earnings

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 gru 2025, 21:32 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 gru 2025, 21:25 UTC

Earnings

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 gru 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 gru 2025, 21:16 UTC

Earnings

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 gru 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 gru 2025, 21:15 UTC

Earnings

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 gru 2025, 21:14 UTC

Earnings

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 gru 2025, 21:14 UTC

Earnings

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

358.72% upside

12 Months Forecast

Average 5 USD 358.72%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

23 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.